Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Li Auto Inc (LI) Price & Performance

IDEXX Laboratories, Inc.Trade
Li Auto IncTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Li Auto Inc — how do they compare? IDEXX Laboratories, Inc. trades at $519.51 (market cap $40.43B), while Li Auto Inc trades at $11.59 (market cap $10.71B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.8× Li Auto Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 1,781,143). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Li Auto Inc for 101 Days on average.

IDXXLI
Market Cap
$40.43B$10.71B
Volume
692,1641,781,143
Sector
HealthConsumer Cyclical
52-Week High
$766.68$23.61
52-Week Low
$504.70$10.69
Typical Hold Time
46 Days101 Days
Enterprise Value
$41.32B$139.58M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.

The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.

Li Auto Inc

Li Auto (LI) trades at $10.99, near its 52-week low, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Revenue declined to $112.31B in 2025, with a net income margin of 1%, while cash flow from operations turned negative. The company faces intense competition in China's EV market, though new model launches like the Li i9 aim to revive growth.

The stock presents a high-risk opportunity, with a consensus price target of $15.18 implying upside, but investors must weigh analyst caution (43.75% buy rating) against execution risks and ongoing cash burn. Near-term performance hinges on delivery recovery and margin improvement amid competitive pressures.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IDXX

No sentiment data available yet.

LI
25% Buy75% Sell
Avg holding period · 101 Days

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →

About Li Auto Inc

Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.

Read more on LI →